We provide you with 20 years of free, institutional-grade data for APLS stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of APLS. Explore the full financial landscape of APLS stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$12,360,262
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Dunlop A. Sinclair | Sale | -31,092 | $22.95 | $713,561 | 2025-09-19 |
| Watson David O. | Sale | -5,000 | $24.34 | $121,700 | 2025-09-18 |
| Chopas James George | Sale | -189 | $24.19 | $4,572 | 2025-09-17 |
| Watson David O. | Sale | -20,000 | $26.17 | $523,400 | 2025-09-12 |
| Sullivan Timothy Eugene | Sale | -10,000 | $27.83 | $278,300 | 2025-09-10 |
| Sullivan Timothy Eugene | Sale | -32,729 | $27.86 | $911,830 | 2025-09-10 |
| Sullivan Timothy Eugene | Derivatives Exercise | 15,000 | 2025-09-10 | ||
| Boucher Kelley | Grant, award...etc | 30,476 | 2025-09-03 | ||
| Chopas James George | Sale | -548 | $28.08 | $15,386 | 2025-09-03 |
| MELTZER LESLIE | Grant, award...etc | 61,804 | 2025-09-02 | ||
| Francois Cedric | Sale | -225,000 | $28.19 | $6,342,750 | 2025-08-29 |
| Watson David O. | Sale | -5,000 | $27.8 | $139,000 | 2025-08-19 |
| Watson David O. | Sale | -5,000 | $19.55 | $97,750 | 2025-07-18 |
| Francois Cedric | Sale | -19,725 | $20.21 | $398,735 | 2025-07-18 |
| Francois Cedric | Derivatives Exercise | 8,997 | 2025-07-18 | ||
| Francois Cedric | Sale | -139,365 | $20.19 | $2,813,278 | 2025-07-16 |
| Francois Cedric | Derivatives Exercise | 66,003 | 2025-07-16 | ||
| Chopas James George | Grant, award...etc | 6,250 | 2025-06-20 | ||
| Watson David O. | Sale | -5,000 | $18.77 | $93,850 | 2025-06-18 |
| Boucher Kelley | Grant, award...etc | 45,095 | 2025-06-11 | ||
| Boucher Kelley | Grant, award...etc | 22,087 | 2025-05-29 | ||
| Deschatelets Pascal | Derivatives Exercise | 12,780 | 2025-05-22 | ||
| WHEELER CRAIG A | Grant, award...etc | 16,483 | 2025-04-21 | ||
| Chopas James George | Sale | -183 | $24.82 | $4,543 | 2025-03-18 |
| Watson David O. | Sale | -5,569 | $25.1 | $139,789 | 2025-03-06 |
| DeLong Mark Jeffrey | Sale | -363 | $28.54 | $10,360 | 2025-02-12 |
| Lewis Karen | Sale | -364 | $29.52 | $10,747 | 2025-01-30 |
| Eisele Jeffrey | Sale | -278 | $29.52 | $8,208 | 2025-01-30 |
| Francois Cedric | Sale | -2,824 | $29.52 | $83,375 | 2025-01-30 |
| Deschatelets Pascal | Sale | -826 | $29.52 | $24,386 | 2025-01-30 |
| DeLong Mark Jeffrey | Sale | -365 | $29.52 | $10,776 | 2025-01-30 |
| Sullivan Timothy Eugene | Sale | -546 | $29.52 | $16,120 | 2025-01-30 |
| Nicholson Nur | Sale | -825 | $29.52 | $24,357 | 2025-01-30 |
| Watson David O. | Sale | -695 | $29.52 | $20,519 | 2025-01-30 |
| Townsend Adam J. | Sale | -695 | $29.52 | $20,519 | 2025-01-30 |
| Lewis Karen | Sale | -1,751 | $30.43 | $53,275 | 2025-01-23 |
| Eisele Jeffrey | Sale | -1,291 | $30.43 | $39,279 | 2025-01-23 |
| Francois Cedric | Sale | -13,551 | $30.43 | $412,296 | 2025-01-23 |
| Deschatelets Pascal | Sale | -3,948 | $30.43 | $120,120 | 2025-01-23 |
| DeLong Mark Jeffrey | Sale | -1,396 | $30.43 | $42,474 | 2025-01-23 |
| Chopas James George | Sale | -1,096 | $30.43 | $33,346 | 2025-01-23 |
| Watson David O. | Sale | -3,323 | $30.43 | $101,104 | 2025-01-23 |
| Sullivan Timothy Eugene | Sale | -3,088 | $30.43 | $93,954 | 2025-01-23 |
| Nicholson Nur | Sale | -3,948 | $30.43 | $120,120 | 2025-01-23 |
| Townsend Adam J. | Sale | -3,323 | $30.43 | $101,104 | 2025-01-23 |
| Lewis Karen | Grant, award...etc | 28,508 | 2025-01-21 | ||
| Lewis Karen | Sale | -1,241 | $29.96 | $37,178 | 2025-01-21 |
| Francois Cedric | Grant, award...etc | 130,662 | 2025-01-21 | ||
| Francois Cedric | Sale | -6,007 | $29.96 | $179,959 | 2025-01-21 |
| Deschatelets Pascal | Grant, award...etc | 15,045 | 2025-01-21 | ||
| Deschatelets Pascal | Sale | -750 | $29.96 | $22,469 | 2025-01-21 |
| Watson David O. | Grant, award...etc | 42,762 | 2025-01-21 | ||
| Watson David O. | Sale | -2,201 | $29.96 | $65,938 | 2025-01-21 |
| DeLong Mark Jeffrey | Grant, award...etc | 28,508 | 2025-01-21 | ||
| DeLong Mark Jeffrey | Sale | -1,235 | $29.96 | $36,998 | 2025-01-21 |
| Chopas James George | Grant, award...etc | 12,591 | 2025-01-21 | ||
| Chopas James George | Sale | -715 | $29.96 | $21,420 | 2025-01-21 |
| Baumal Caroline | Grant, award...etc | 39,594 | 2025-01-21 | ||
| Baumal Caroline | Sale | -1,853 | $29.96 | $55,513 | 2025-01-21 |
| Townsend Adam J. | Sale | -2,201 | $29.96 | $65,938 | 2025-01-21 |
| Nicholson Nur | Grant, award...etc | 36,426 | 2025-01-21 | ||
| Nicholson Nur | Sale | -2,145 | $29.96 | $64,260 | 2025-01-21 |
| Sullivan Timothy Eugene | Grant, award...etc | 45,929 | 2025-01-21 | ||
| Sullivan Timothy Eugene | Sale | -1,730 | $29.96 | $51,828 | 2025-01-21 |
| Eisele Jeffrey | Sale | -264 | $28.7 | $7,577 | 2025-01-14 |
| Francois Cedric | Sale | -6,247 | $28.7 | $179,302 | 2025-01-14 |
| Lewis Karen | Sale | -1,599 | $28.7 | $45,895 | 2025-01-14 |
| Deschatelets Pascal | Sale | -2,288 | $28.7 | $65,670 | 2025-01-14 |
| DeLong Mark Jeffrey | Sale | -1,599 | $28.7 | $45,895 | 2025-01-14 |
| Chopas James George | Sale | -783 | $28.7 | $22,474 | 2025-01-14 |
| Sullivan Timothy Eugene | Sale | -2,170 | $28.7 | $62,284 | 2025-01-14 |
| Watson David O. | Sale | -4,965 | $28.7 | $142,506 | 2025-01-14 |
| Nicholson Nur | Sale | -2,632 | $28.7 | $75,544 | 2025-01-14 |
| Townsend Adam J. | Sale | -2,685 | $28.7 | $77,065 | 2025-01-14 |
| Walbert Keli | Grant, award...etc | 9,090 | 2025-01-10 | ||
| Baumal Caroline | Sale | -2,816 | $33.81 | $95,215 | 2025-01-08 |
| Sullivan Timothy Eugene | Derivatives Exercise | 11,096 | 2025-01-03 | ||
| Chan Gerald | Grant, award...etc | 6,267 | 2025-01-03 | ||
| Machiels Alec | Grant, award...etc | 6,267 | 2025-01-03 | ||
| O'Brien Stephanie Monaghan | Grant, award...etc | 6,267 | 2025-01-03 | ||
| FONTEYNE PAUL R. | Grant, award...etc | 6,267 | 2025-01-03 | ||
| Dunlop A. Sinclair | Grant, award...etc | 6,267 | 2025-01-03 | ||
| Eisele Jeffrey | Sale | -63 | $33.09 | $2,085 | 2024-12-27 |
| Watson David O. | Sale | -5,000 | $34.23 | $171,175 | 2024-12-13 |
| Dunlop A. Sinclair | Derivatives Exercise | 4,600 | 2024-09-24 | ||
| Dunlop A. Sinclair | Sale | -37,000 | $36.09 | $1,335,330 | 2024-09-17 |
| Chopas James George | Sale | -192 | $36.21 | $6,952 | 2024-09-17 |
| Chopas James George | Sale | -550 | $39.49 | $21,720 | 2024-09-04 |
| DeLong Mark Jeffrey | Derivatives Exercise | 5,201 | 2024-08-13 | ||
| Dunlop A. Sinclair | Derivatives Exercise | 900 | 2024-07-01 | ||
| Dunlop A. Sinclair | Sale | -37,000 | $39.22 | $1,451,140 | 2024-06-21 |
| Deschatelets Pascal | Derivatives Exercise | 24,500 | 2024-05-21 | ||
| Deschatelets Pascal | Sale | -78,907 | $42.15 | $3,325,962 | 2024-05-09 |
| Deschatelets Pascal | Derivatives Exercise | 78,907 | 2024-05-09 | ||
| Dunlop A. Sinclair | Derivatives Exercise | 1,500 | 2024-04-15 | ||
| Deschatelets Pascal | Sale | -69,107 | $54.12 | $3,739,829 | 2024-04-09 |
| Deschatelets Pascal | Derivatives Exercise | 69,107 | 2024-04-09 | ||
| Sullivan Timothy Eugene | Sale | -4,000 | $58.66 | $234,640 | 2024-04-02 |
| Sullivan Timothy Eugene | Derivatives Exercise | 4,000 | 2024-04-02 | ||
| Dunlop A. Sinclair | Sale | -18,681 | $57.18 | $1,068,161 | 2024-03-20 |
| DeLong Mark Jeffrey | Sale | -9,913 | $56.9 | $564,050 | 2024-03-19 |
| Chopas James George | Sale | -184 | $56.46 | $10,389 | 2024-03-18 |
The information provided in this report about APLS stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Apellis Pharmaceuticals, Inc(NASDAQ:APLS) 
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials fo...
Website: http://www.apellis.com
Founded: 2009
Full Time Employees: 350
Sector: Healthcare
Industry: Biotechnology